Program
flonoltinib maleate
Also written as “Flonoltinib Maleate” and “Flonoltinib Maleate Tablets”.
Its studies are led by Chengdu Zenitar Biomedical Technology.
Furthest: phase 2, since Dec 19, 20252 company-led studies, 1 open or runningNext primary completion: Dec 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Zenitar Biomedical Technology | 21 open or running | phase 2since Dec 19, 2025 | Mar 6, 2024 | Dec 30, 2027phase 2 · NCT07443306 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2024First study: phase 1 study in Heathly SubjectsFirst studyNCT06387966 · 40 enrolled · China
- Dec 19, 2025Phase 2 study in MFPhase 2 reachedNCT07443306 · 64 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 2 study in MFNCT07443306
TargetBeta
“The maleate salt form of flonoltinib, an orally bioavailable dual inhibitor of both Janus-associated kinase 2 (JAK2) and of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 18 |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 7 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07443306MF · China | 2 | Recruiting | Dec 30, 2027 | 64 |
| NCT06387966Heathly Subjects · China | 1 | Completed | Aug 15, 2024 | 40 |
How it is read
Names in the registry
- “Flonoltinib Maleate”, 1 entry
- “Flonoltinib Maleate Tablets”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.